Professionals
Labiana Health has been recognized as a success story on BME Growth by Bolsas y Mercados Españoles (BME), which highlights the company’s evolution since its IPO and its growth as a pharmaceutical group specializing in human and animal health, being the first veterinary pharmaceutical laboratory to be listed on the stock exchange in Spain.
Labiana, the pharmaceutical laboratory specializing in animal and human health and listed on BME Growth, will bring its new line of products for women’s health and wellness to CPHI, the most important annual trade fair in the pharmaceutical sector, taking place from October 28 to 30 in Germany.
Specifically, Labiana — which specializes in the development and manufacturing of both its own products and those for third parties (CDMO) — will present, as part of its human health portfolio, two food supplements and one cosmetic product.
Labiana Health, the Spanish pharmaceutical group specializing in human and animal health, has published a communication through BME Growth, the Spanish alternative stock market where it is listed, disclosing an unaudited preliminary report on its consolidated financial results for the first half of the fiscal year in 2025.
Labiana, el primer laboratorio veterinario español cotizado en Bolsa, ha reforzado su división especializada en pequeños animales.
Ataxxa, medicamento distribuido por Labiana, autorizado para la reducción del riesgo de infección por Leishmania.
